Precision molecular diagnostics company DiaCarta has received an emergency use authorization (EUA) from the US Food and Drug Administration for its QuantiVirus MPXV test, a real-time multiplex PCR test intended for the qualitative detection of monkeypox virus DNA in human lesion swab specimens.
The test from the Pleasanton, CA-based company is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?